Jones P, et al. - This study entails an appraisal of alirocumab (ALI) for safety and lipid-lowering efficacy among patients with or without clinical atherosclerotic cardiovascular disease (ASCVD). In both patient groups, ALI demonstrated good tolerability, generally. Treatment with ALI afforded substantial reductions in LDL-C levels and allowed greater LDL-C goal achievement, compared with controls.